# A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy

> **NCT01184885** · EARLY_PHASE1 · COMPLETED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University** · enrollment: 7 (actual)

## Conditions studied

- Lymphoid Malignancies (New or Relapsed)
- Acute Lymphoblastic Leukemia
- Burkitt Lymphoma
- Lymphoblastic Lymphoma
- Mantle Cell Lymphoma
- Adult T-cell Leukemia/Lymphoma

## Interventions

- **DRUG:** Hyper-CVAD
- **DRUG:** Sirolimus

## Key facts

- **NCT ID:** NCT01184885
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07
- **Primary completion:** 2011-03
- **Final completion:** 2013-04
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2025-05-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01184885

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01184885, "A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01184885. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*